QCG
BPMC

Quadrant Capital Group’s Blueprint Medicines BPMC Stock Holding History

Quadrant Capital Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3
Closed -$266 – 1517
2025
Q1 		$266 Hold
3
– – ﹤0.01% 2702
2024
Q4 		$262 Sell
3
-37
-93% -$3.39K ﹤0.01% 2690
2024
Q3 		$3.7K Hold
40
– – ﹤0.01% 2380
2024
Q2 		$4.31K Hold
40
– – ﹤0.01% 2335
2024
Q1 		$3.79K Sell
40
-22
-35% -$1.89K ﹤0.01% 2380
2023
Q4 		$5.72K Buy
62
+59
+1,967% +$3.82K ﹤0.01% 2238
2023
Q3 		$151 Sell
3
-139
-98% -$7.43K ﹤0.01% 2658
2023
Q2 		$8.97K Buy
142
+139
+4,633% +$7.56K ﹤0.01% 2042
2023
Q1 		$135 Sell
3
-27
-90% -$1.22K ﹤0.01% 2695
2022
Q4 		$1.31K Buy
30
+9
+43% +$432 ﹤0.01% 2494
2022
Q3 		$1K Sell
21
-48
-70% -$3.08K ﹤0.01% 2476
2022
Q2 		$3K Buy
69
+60
+667% +$3.52K ﹤0.01% 2088
2022
Q1 		$1K Sell
9
-5
-36% -$359 ﹤0.01% 2255
2021
Q4 		$1K Sell
14
-26
-65% -$2.72K ﹤0.01% 2258
2021
Q3 		$4K Buy
40
+31
+344% +$2.89K ﹤0.01% 1922
2021
Q2 		$1K Sell
9
-16
-64% -$1.47K ﹤0.01% 2226
2021
Q1 		$2K Buy
25
+21
+525% +$2.1K ﹤0.01% 2027
2020
Q4 		$0 Hold
4
– – ﹤0.01% 2301
2020
Q3 		$0 Hold
4
– – ﹤0.01% 2168
2020
Q2 		$0 Sell
4
-965
-100% -$65.3K ﹤0.01% 2224
2020
Q1 		$56K Buy
969
+864
+823% +$55.6K 0.01% 826
2019
Q4 		$8K Sell
105
-254
-71% -$19K ﹤0.01% 1949
2019
Q3 		$26K Hold
359
– – ﹤0.01% 1498
2019
Q2 		$33K Buy
+359
New +$29.6K 0.01% 1386

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Quadrant Capital Group's BPMC Position: Q2 2025 in Review

Quadrant Capital Group sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 3 shares — an estimated $266 sold.

Quadrant Capital Group first reported a position in BPMC in Q2 2019 and held it in 24 quarters. The position peaked at $56K in Q1 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Quadrant Capital Group reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 3 Blueprint Medicines shares in Q2 2025, an estimated $266.
  • Quadrant Capital Group first reported a position in Blueprint Medicines in Q2 2019 and held it in 24 quarters.
  • Quadrant Capital Group's Blueprint Medicines position peaked at $56K in Q1 2020.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.